SPECTROPHOTOMETRIC METHOD FOR ESTIMATION OF RABEPRAZOLE SODIUM IN TABLETS
Gulshan Pandey*, Koushlesh Mishra
Apollo college of pharmacy, Opposite of govt. veterinary college, Anjora, Distt.- Durg, (C.G.) India
Email: gulshan64@yahoo.co.in

Article Received on: 10/01/13 Revised on: 08/02/13 Approved for publication: 12/03/13

ABSTRACT
A simple, rapid, accurate, economical and reproducible spectrophotometric method for estimation of rabeprazole sodium (RAB) has been developed. The method employs estimation by straight line equation obtained from calibration curve of Rabeprazole IRJP is an official publication of Moksha Publishing House. Website: www.mokshaph.com

INTRODUCTION
Rabeprazole sodium I.P. or 2-[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl] methyl]sulfinyl]-1H-benzimidazole, is a selective and irreversible proton pump inhibitor and it has proven efficacy in healing, symptoms relief and prevention of relapse of gastric ulcer, duodenal ulcer and gastroesophageal reflux disease. Various chromatographic and spectrometric methods have been developed for quantification of rabeprazole sodium. No doubt, available chromatographic methods are accurate and precise with good reproducibility, but the cost of analysis is quite high owing to expensive instrumentation, reagent required, expertise and more time per sample analysis, this makes these chromatographic methods unsuitable for routine analysis. Variations in columns and instruments accuracy due to manufacturer to manufacturer variation complicate transfer of these HPLC methods. Extensive literature survey revealed that only a single UV method is however reported till date for the estimation of rabeprazole sodium in tablet dosage form. That’s why it was thought to develop new simple, economical, accurate, reproducible and rapid analytical methods for estimation of rabeprazole sodium in tablets by UV spectroscopy.

Reagents and Chemicals
Analytical pure standard samples of rabeprazole sodium were supplied as gift sample by Vama Pharma. Pvt. Ltd. Nagpur (M.H.) India and used without further purification. The Pharmaceutical dosage form used in this study was a Rabimac tablet (Label claim: 20mg of rabeprazole sodium I.P. as sustained release tablet) manufactured by Macleod Pvt. Ltd. Methanol LR grade was purchased from CDH, Rankem and Qualigens, and inbuilt distilled water was used. 20% v/v aqueous methanol was used as solvent.

Preparation of Standard Stock Solution
The stock solution of standard rabeprazole sodium was prepared by dissolving approximately 5mg rabeprazole sodium in 10ml 20% v/v aqueous methanol the suspension was quantitatively transferred into a 25ml calibrated volumetric flask and volume was made up to 25ml with solvent. The strength of the resulting solution will be approx.200 µg/ml.

Preparation of Calibration Curve
In a series of 10ml volumetric flasks, sufficient aliquot of the standard stock solution (200 µg /ml) were transferred and diluted with 20% v/v aqueous methanol so as to give several dilutions of 4.08 – 24.5µg/ml. The absorbance was measured against 20% v/v aqueous methanol at 284.0nm (λmax of rabeprazole sodium)

Table 1: Data for Calibration Curve of Rabeprazole Sodium

<table>
<thead>
<tr>
<th>Concentration µg/ml</th>
<th>Absorbance at 284.0nm</th>
</tr>
</thead>
<tbody>
<tr>
<td>4.08</td>
<td>0.12728</td>
</tr>
<tr>
<td>8.16</td>
<td>0.24071</td>
</tr>
<tr>
<td>12.24</td>
<td>0.35016</td>
</tr>
<tr>
<td>16.32</td>
<td>0.48871</td>
</tr>
<tr>
<td>20.4</td>
<td>0.61162</td>
</tr>
<tr>
<td>24.5</td>
<td>0.71783</td>
</tr>
</tbody>
</table>

MATERIAL AND METHOD
Instrumentation
UV/visible double beam spectrophotometer (Jasco Model V530) was employed with spectral bandwidth of 1nm and wavelength accuracy of ±0.3 nm, with a pair of 1 cm matched quartz cells.(Optigalss).
Preparation of Sample Stock Solution
Twenty tablets were powdered and weight equivalent to approx. 10 mg of rabeprazole sodium was dissolved in 20 ml of 20% v/v aqueous methanol. The suspension was sonicated vigorously for 5 min to completely dissolve the remaining drug in powder. The solution after filtrations through Whatman filter paper no. 41 was quantitatively transferred to 100 ml calibrated volumetric flask and the volume was then made up to 100 ml with 20% v/v aqueous methanol by continuously washing filter paper to quantitatively transfer the total amount of drug. The strength of resulting solution will be of approx. 100 µg/ml.

Theory and calculation
Validation
The developed method for the estimation of RAB was validated as per ICH guidelines (ICH 1996). The described method has been validated for linearity, precision, accuracy, specificity, and robustness.

Linearity
Least square regression analysis was carried out for the slope, intercept and correlation coefficient (Table I). The linear fit of the system was illustrated graphically. The linearity range was found to be 4.08 – 24.5 µg/ml Regression equation for RAB was \( y = 0.00298 \times + 0.0013 \) (\( r^2 = 0.9992 \)).

Accuracy
This experiment was performed at three levels in which sample stock solutions were spiked with standard drug solution containing 80, 100 and 120% of sample solution of the rabeprazole sodium. Three replicate samples of each concentration level were prepared and the % recovery at each level (n = 3), and mean % recovery (n=9) were determined. The means of %recovery (%RSD) were found to be low values <2 (Table III). These results revealed that any small change in the drug concentration in the solution could be accurately determined by the proposed analytical methods.

Table 3: Results of Accuracy Experiment Using Proposed Method

<table>
<thead>
<tr>
<th>Spike Level</th>
<th>Analyte conc. (µg/ml)</th>
<th>Conc. Spike (µg/ml)</th>
<th>Conc. Found (µg/ml)</th>
<th>% Recovery Mean</th>
<th>% Recovery Mean</th>
<th>% S.D</th>
</tr>
</thead>
<tbody>
<tr>
<td>80%</td>
<td>10.07</td>
<td>7.84</td>
<td>7.88</td>
<td>101.275</td>
<td>101.061</td>
<td>1.617</td>
</tr>
<tr>
<td>100%</td>
<td>10.07</td>
<td>10.08</td>
<td>9.91</td>
<td>98.313</td>
<td>98.247</td>
<td>1.611</td>
</tr>
<tr>
<td>120%</td>
<td>10.07</td>
<td>12.32</td>
<td>12.04</td>
<td>97.727</td>
<td>97.591</td>
<td>1.613</td>
</tr>
</tbody>
</table>

Precision
The precision of the proposed method was evaluated by carrying out nine independent assays of test sample (10, 15, 20 µg/ml). RSD (%) of nine assay values obtained was calculated. Intermediate precision was carried out by analyzing the samples by a different analyst with deferent reagent on same instrument. No statistically significant difference was observed. The resultant data was presented in table IV. %RSD values were not more than 2.0% in all the cases. RSD values found for all three analytical methods were well with in the acceptable range indicating that these all methods have excellent repeatability and intermediate precision.

Specificity
Specificity is the ability to measure accurately and specifically the analyte of interest in the presence of other components that may be expected to be present in the sample matrix. It was found that the proposed method was specific because there is no interference of other active ingredients and excipients, ensuring that the peak response is due only to a single component. Based on the results, obtained from the analysis of standard drug and samples using the described method, it can be concluded that the method is specific for estimation of RAB in presence of degradants.
The proposed validated three spectrophotometric methods are from the regression equation of standard drug. Figure 3 illustrates overlaid spectra obtained from RAB standard solution and from the assay of Rabimac®. The observed concentration of RAB was found to be 20.09±0.241mg (mean±SD) for Rabimac®. The results of the assay (n = 9) undertaken yielded 100.45 % (%RSD = 0.24) of label claim for RAB in Rabimac® shown in table V. The results of the assay indicate that the method is selective for the estimation of RAB without interference from the excipients used to formulate and produce these tablets.

<table>
<thead>
<tr>
<th>Drug</th>
<th>Label claim mg/tab</th>
<th>% of label claim estimated</th>
<th>S.D.</th>
<th>% R.S.D.</th>
<th>S.E.</th>
</tr>
</thead>
<tbody>
<tr>
<td>RAB</td>
<td>20</td>
<td>100.45</td>
<td>0.2403</td>
<td>0.2414</td>
<td>0.0801</td>
</tr>
</tbody>
</table>

Table 5: Results of Commercial Formulation Analysis

* Average of nine determination, S.D.: Standard deviation, R.S.D.: Relative standard deviation, S.E.: Standard error

![Figure 3: Comparison of Spectra of Rabeprazole Sodium from Tablet and Standard Drug In 20% v/v Aqueous Methanol (conc. approx 12µg/ml)](Image)

RESULTS AND DISCUSSION
The proposed method utilizes UV/visible double beam spectrophotometer (Jasco Model V530) with spectral bandwidth of 1nm and wavelength accuracy of ±0.3 nm. The optical characteristics such as absorption maxima, beer's law limit, absorptivity, correlation coefficient (r), slope (m), y-intercept (c) were calculated and shown in table 2. The repeatability, reproducibility were found to be good as evident by the low standard deviation value (less than 2) in all cases reported in table 4. The percentage recovery values obtained were 98.966 reported in table 3. This shows that there is no interference of the excipients in the analysis. The analysis result of tablet formulations are in good agreement with the official standard reported in table 5.

CONCLUSION
The proposed validated three spectrophotometric methods are simple, rapid, accurate, precise and inexpensive and hence can be used for the routine analysis of RAB in tablet. The sample recovery for all three methods was in good agreement with their respective label claims, which suggested non-interference of formulation additives in estimation.

ACKNOWLEDGEMENT
The author is thankful to prof. A.K. Pathak head, department of Pharmacy, Barkatulla University Bhopal, (M.P.) for providing facilities to carry out proposed work and Vama Pharma. Pvt. Ltd. Nagpur (M.H.) India for the gift sample rabeprazole sodium.

REFERENCES
1. Indian Pharmacopoeia, Volume-2, Indian Pharmacopoeia Commission, Ghaziabad, Controller of publication, New Delhi, 2007.

Cite this article as:

Source of support: Nil, Conflict of interest: None Declared